Source: https://journal.niidi.ru/jofin/article/view/57
Timestamp: 2019-04-22 19:55:24+00:00

Document:
В обзоре представлены современные подробные сведения о различных аспектах проблемы парвовирусной инфекции. На основании анализа данных литературы описаны этиология, эпидемиология заболевания, его клинические проявления. Особое внимание обращено на механизмы патологического воздействия парвовируса на плод. Широко освещены возможности оценки риска врожденной парвовирусной инфекции, антенатальной диагностики, интерпретации результатов различных лабораторных и инструментальных методов исследований. Описаны терапевтические подходы в различных клинических ситуациях, обсуждаются возможности профилактики заболевания.
1. Cossart, Y.E. Parvovirus-like particles in human sera /Y.E. Cossart [et al.] // Lancet. – 1975. –V. 1, № 7898. –P. 72–73.
2. Дудина, К.Р. Парвовирусная 19 инфекция и ее клинические проявления / К.Р. Дудина, О.О. Знойко, Н.Д. Ющук // Тер. архив. –2007. –Т. 79, № 11. –С. 75–78.
3. Nicolay, N. Clinical and epidemiological aspects of parvovirus B19 infections in Ireland, January 1996–June 2008 / N. Nicolay, S. Cotter // Euro Surveill. – 2009. –V. 14. –P. 1–5.
4. Anderson, M.J. Experimental parvoviral infection in humans / M. J. Anderson [et al.] // J. Infect. Dis. – 1985. –V. 152. –P. 257–265.
5. Plummer, F.A. An erythema infectiosum–like illness caused by human parvovirus infection / F.A. Plummer [et al.] // N. Engl. J. Med. –1985. –V. 3, № 13. –Р. 74–79.
6. Servant-Delmas, A. Advances in human B19 erythrovirus biology / A. Servant-Delmas [et al.] // J. Virol. –2010. –V. 84, № 19 –Р. 9658–9665.
7. Servant, A. Genetic diversity within human erythroviruses: identification of three genotypes / A. Servant [et al.] // J. Virol. –2002. –V. 76. –P. 9124–9134.
8. Allander, T. Cloning of a human parvovirus by molecular screening of respiratory tract samples / T. Allander [et al.] //Proc. Natl. Acad. Sci. U. S. A. –2005. –V.102. –P. 12891– 12896.
9. Jones, M.S. New DNA viruses identified in patients with acute viral infection syndrome / M.S. Jones [et al.] // J. Virol. –2005. – V. 79. –P. 8230–8236.
10. Kaufmann, B. The structure of human parvovirus B19 / B. Kaufmann, A.A. Simpson, M.G. Rossmann // Proc. Natl. Acad. Sci. U. S. A. –2004. –V. 101. –P. 11628–11633.
11. Norja, P. Bioportfolio: lifelong persistence of variant and prototypic erythrovirus DNA genomes in human tissue /P. Norja [et al.] // Proc. Natl. Acad. Sci. U. S. A. –2006. –V. 103. –P. 7450–7453.
12. Zádori, Z. A viral phospholipase A2 is required for parvovirus infectivity / Z. Zádori [et al.] // Dev. Cell –2001. –V. 1. –P. 291–302.
13. Hübschen, J.M. Phylogenetic analysis of human parvovirus B19 sequences from eleven different countries confirms the predominance of genotype 1 and suggests the spread of genotype 3b / J.M. Hübschen [et al.] // J. Clin. Microbiol. – 2009. –V. 47. –P. 3735–3738.
14. Okochi, K. Nakatani antigen and human parvovirus (B19) / K. Okochi [et al.] // Lancet. – 1984. –V. 1. –P. 160–161.
15. Anderson, M.J. Experimental parvoviral infection in humans / M.J. Anderson [et al.] // J. Infect. Dis. – 1985. –V. 152. – P. 257–265.
16. Courouce, A.M. Human parvovirus infections in France /A.M. Courouce [et al.] // Lancet. – 1984. –V. 1. –P. 160.
17. Enders, M. Current epidemiological aspects of human parvovirus B19 infection during pregnancy and childhood in the western part of Germany / M. Enders, A. Weidner, G. Enders // Epidemiol. Infect. –2007. –V. 135. –P. 563–569.
18. Kelly, H.A. The age-specific prevalence of human parvovirus immunity in Victoria, Australia compared with other parts the world / H.A. Kelly [et al.] // Epidemiol. Infect. –2000. – V. 124. –P. 449–457.
19. Mossong, J. Parvovirus B19 infection in five European countries: seroepidemiology, force of infection and maternal risk of infection / J. Mossong [et al.] // Epidemiol. Infect. – 2008. – V. 136. – P. 1059–1068.
20. Stelma, F.F. Occupational risk of human cytomegalovirus and parvovirus B19 infection in female day care personnel in the Netherlands; a study based on seroprevalence / F.F. Stelma [et al.] // Eur. J. Clin. Microbiol. Infect. Dis. –2009. –V. 28. –P. 393–397.
21. Elnifro, E. Seroprevalence of parvovirus B19 among pregnant women in Tripoli, Libya / E. Elnifro [et al.] // J. Infect. ev. Ctries. – 2009. –V. 3. –P. 218–220.
22. Nascimento, J.P. The prevalence of antibody to human parvovirus B19 in Rio de Janeiro, Brazil / J.P. Nascimento [et al.] // Rev. Inst. Med. Trop. Sao Paulo. – 1990. –V. 32. –P.41–45.
23. Gilbert, N.L. Seroprevalence of parvovirus B19 infection in daycare educators / N.L. Gilbert [et al.] // Epidemiol. Infect. – 2005. – V. 133. –P. 299–304.
24. Филатова, Е.В. Определение маркеров парвовируса В19 в крови доноров / Е.В. Филатова [и др.] // Журн. микробиологии. –2010. –№ 5. –С. 67–70.
25. Valeur-Jensen, A.K. Risk factors for parvovirus B19 infection in pregnancy / A.K. Valeur-Jensen [et al.] // J. Am. Med. Assoc. – 1999. –V. 281. –P. 1099–1105.
26. Anderson, L.J. Risk of infection following exposures to human parvovirus B19 / L.J. Anderson [et al.] // Behring Inst. Mitt. –1990. –V. 85. –P. 60–63.
27. Gillespie, S.M. Occupational risk of human parvovirus B19 infection for school and day-care personnel during an outbreak of erythema infectiosum / S.M. Gillespie [et al.] // J. Am. Med. Assoc. –1990. –V. 263. –P. 2061–2065.
28. Островская, О.В. Внутриутробные инфекции, клинико-морфологическая оценка современной специфической диагностики : дисc. … докт. мед. наук: 14.00.09, 03.00.06 / О.В. Островская. –Хабаровск : ГОУ ВПО ДВГМУ Росздраваб 2009. –319 с.
29. Цвиркун, О.В. Клинико-эпидемиологические особенности вспышки инфекционной эритемы / О.В. Цвиркун [и др.] // Эпидемиология и вакцинопрофилактика. –2005. –№ 2. –С. 21–25.
30. Koch, W.C. Fifth (human parvovirus) and sixth (herpesvirus 6) diseases / W.C. Koch // Curr. Opin. Infect. Dis. – 2001. – V. 14. –P. 343–356.
31. Матвеев, В.А. Клинико-лабораторная характеристика В19 парвовирусной инфекции / В.А. Матвеев [и др.] // Инфекционные болезни. –2008. –Т. 6, № 3. –С. 33–37.
32. Врожденные инфекции: клиника, диагностика, лечение, профилактика : учебн. пособие для врачей / под ред. заслуженного деятеля науки РФ академика РАМН Ю.В. Лобзина. – СПб. – 62 с.
33. Savarese, I. Atypical manifestations of congenital parvovirus B19 infection / I. Savarese [et al.] // Eur. J. Pediatr. – 2008. –V. 167, № 12. –Р. 1463–1466.
34. Douvoyianni, M. Neurologic manifestations associated with parvovirus B19 infection / M. Douvoyianni, N. Litman, D.L. Goldman // Clin. Infect. Dis. – 2009. –V. 48, № 12. – Р. 1713–1723.
35. Broliden, K. Detection of parvovirus B19, cytomegalovirus and enterovirus infections in cases of intrauterine fetal death / K. Broliden [et al.] // J. Perinat. Med. – 2004. –V. 32, № 6. –Р. 516–521.
36. Gustafsson, I. Evaluation of parvovirus B19 infection in children with malignant or hematological disorders / I. Gustafsson [et al.] // Clin. Infect. Dis. – 2010. – V. 50, № 10. –Р.
37. Carraca, T. Early signs of cardiac failure: a clue for parvovirus infection screening in the first trimester? / T. Carraca [et al.] // Fetal. Diagn. Ther. – 2011. –V. 30, № 2. –Р. 150–152.
38. Morgan-Capner, P. Guidelines on the management of, and exposure to, rash illness in pregnancy (including consideration of relevant antibody screening programmes in pregnancy) / P. Morgan-Capner, N.S. Crowcroft // Commun. Dis. Public Health – 2002. – V. 5. –P. 59–71.
39. Sarfraz, A.A. Maternal human parvovirus B19 infection and the risk of fetal death and low birthweight: a case-control study within 35 940 pregnant women / A.A. Sarfraz [et al.] // BJOG. – 2009. – V. 116, № 11. –Р. 1492–1498.
40. Simms, R.A. Management and outcome of pregnancies with parvovirus B19 infection over seven years in a tertiary fetal medicine unit / R.A. Simms [et al.] // Fetal Diagn. Ther. – 2009. – V. 25. –P. 373–378.
41. Rodis, J.F. Management of parvovirus infection in pregnancy and outcomes of hydrops: a survey of members of the Society of Perinatal Obstetricians / J.F. Rodis [et al.] // Am. J. Obstet. Gynecol. – 1998. –V. 179. –P. 985–988.
42. Nagel, H.T. Long-term outcome after fetal transfusion for hydrops associated with parvovirus B19 infection / H.T. Nagel [et al.] // Obstet. Gynecol. – 2007. –V. 109. –P. 42–47.
43. Moore, L. A report of human parvovirus B19 infection in hydrops fetalis. First Australian cases confirmed by serology and immunohistology / L. Moore [et al.] // Med. J. Aust. – 1993. –V. 159, № 5. – Р. 344–345.
44. O’Malley, A. Parvovirus infects cardiac myocytes in hydrops fetalis / A. O’Malley [et al.] // Pediatr. Dev. Pathol. – 2003. – V. 6, № 5. –Р. 414–420.
45. Nunoue, T. Human fetal infection with parvovirus B19: maternal infection time in gestation, viral persistence and fetal prognosis / T. Nunoue, K. Kusuhara, T. Hara // Pediatr. Infect. Dis. J. – 2002. –V. 21, № 12. –Р. 1133–1136.
46. Trotta, M. Intrauterine parvovirus B19 infection: early prenatal diagnosis is possible / M. Trotta [et al.] // Int. J. Infect. Dis. – 2004. –V. 8, № 2. – Р. 130–131.
47. Enders, M. Fetal morbidity and mortality after acute human parvovirus B19 infection in pregnancy: prospective evaluation of 1018 cases / M. Enders, Weidner A., Zoellner I., Searle K., Enders G. // Prenat. Diagn. – 2004. –V. 24, № 7. – Р. 513–518.
48. Morey, A.L. Clinical and histopathological features of parvovirus B19 infection in the human fetus / A.L. Morey [et al.] // Br. J. Obstet. Gynaecol. – 1992. –V. 99, № 7. –Р. 566–574.
49. Riipinen, A. Parvovirus b19 infection in fetal deaths / A. Riipinen [et al.] // Clin. Infect. Dis. –2008. –V. 47, № 12. –Р. 1519–1525.
50. Bruu, A.L. Evaluation of five commercial tests for detection of immunoglobulin M antibodies to human parvovirus B19 / A.L. Bruu, S.A. Nordbo // J. Clin. Microbiol. – 1995. – V. 33. –P. 1363–1365.
51. Tolfvenstam, T. Evaluation of serological assays for identification of parvovirus B19 immunoglobulin M / T. Tolfvenstam, U. Ruden, K. Broliden // Clin. Diagn. Lab. Immunol. – 1996. – V. 3. –P. 147–150.
52. Butchko, A.R. Comparison of three commercially available serologic assays used to detect human parvovirus B19- specific immunoglobulin M (IgM) and IgG antibodies in sera of pregnant women / A.R. Butchko, J.A. Jordan // J. Clin. Microbiol. – 2004. –V. 42. –P. 3191–3195.
53. Koppelman, M.H.G.M. Quantitative real-time detection of parvovirus B19 DNA in plasma / M.H.G.M. Koppelman [et al.] // Transfusion. –2004. –V. 44, № 1. –P. 97–103.
54. Simms, R.A. Management and outcome of pregnancies with parvovirus B19 infection over seven years in a tertiary feoftal medicine unit / R.A. Simms [et al.] // Fetal. Diagn. Ther. – 2009. – V. 25, № 4. –Р. 373–378.
55. Matsuda, H. Intrauterine therapy for parvovirus B19 infected symptomatic fetus using B19 IgG-rich high titer gammaglobulin/H. Matsuda [et al.] // J. Perinat. Med. – 2005. –V. 33, № 6. – Р. 561–563.
56. Курцер, М.А. Неиммунная водянка плода: диагностика и тактика / М.А. Курцер [и др.] //Акушерство и гинекология. –2009. –№ 2. –С. 37–40.
57. Сидорова, И.С. Внутриутробная инфекция: ведение беременности, родов и послеродового периода : учебн. пособие / И.С. Сидорова, И.О. Макаров, Н.А. Матвиенко. – М.: МЕДпресс-информ, 2008. –160 с.
58. Palmer, G.A. A nonproliferating parvovirus vaccine vector elicits sustained, protective humoral immunity following a single intravenous or intranasal inoculation / G.A. Palmer [et al.] // J. Virol. – 2004. – V. 78. –P. 1101–1108.
59. Ballou, W.R. Safety and immunogenicity of a recombinant parvovirus B19 vaccine formulated with MF59C / W.R. Ballou [et al.] //J. Infect. Dis. – 2003. –V. 187. –P. 675–678.

References: V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V.